Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Other Publications
    • ajnr

User menu

  • Subscribe
  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

  • Subscribe
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds
LetterLETTER

The New Standard for Performance of Intracranial Angioplasty and Stent Placement after Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis (SAMMPRIS) Trial

S.A. Chaudhry, M. Watanabe and A.I. Qureshi
American Journal of Neuroradiology December 2011, 32 (11) E214; DOI: https://doi.org/10.3174/ajnr.A2919
S.A. Chaudhry
aZeenat Qureshi Stroke Research Center University of Minnesota Minneapolis, Minnesota
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Watanabe
aZeenat Qureshi Stroke Research Center University of Minnesota Minneapolis, Minnesota
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A.I. Qureshi
aZeenat Qureshi Stroke Research Center University of Minnesota Minneapolis, Minnesota
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

Percutaneous transluminal angioplasty and stent placement (PTAS) has become a treatment option for selected patients with symptomatic intracranial arterial stenosis.1 The Stent Placement versus Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial was initiated in October of 20082 to compare PTAS with aggressive medical managements. The intent of the PTAS treatment was to prevent the primary end point (any stroke or death within 30 days after enrollment or stroke in the territory of the symptomatic intracranial artery beyond 30 days) during a mean follow-up of 2 years in high-risk patients with symptomatic stenosis of a major intracranial artery. Details about the study design, patient enrollment, and follow-up have been published previously.2 The study was powered to detect a relative 35% reduction in the rate of the primary end point from stent placement based on the log-rank test with an α of .05% and 80% power.

On April 5, 2011, the trial was prematurely halted at the recommendation of the Safety Monitoring Board appointed by the National Institutes of Health. This decision was based on the considerably high 30-day stroke and death rate in the PTAS group (14%) compared with the medical management group (5.8%).3 The 30-day rate of stroke or death in the PTAS group was substantially higher than the rates previously reported (rates ranging from 4.4% to 9.6%).4,5 Of the 33 strokes in the PTAS group that occurred within 30 days after enrollment, 25 occurred within 1 day after the procedure and 8 occurred 2–6 days later.3 These results raised the question of whether the rate of 30-day events can be reduced in patients undergoing PTAS by more appropriate patient selection and greater operator experience. Another important question is: What is the rate of 30-day events required for PTAS to be beneficial in reducing the long-term rate of ipsilateral stroke?

We performed an analysis on the basis of the results provided by SAMMPRIS to determine the 30-day rate of stroke and/or death required to achieve a 35% relative risk reduction of the primary end point (composite of 1 month stroke and/or death and ipsilateral stroke beyond 1 month) among the PTAS-treated group compared with the medically treated group at 1 year follow-up. Our analysis found that if the 30-day rate of stroke and/or death had been 3.8% in the PTAS group, then the relative risk reduction by PTAS would have met the primary hypothesis of the trial (Fig 1). The analysis assumes that the rate of events in patients treated with PTAS after 1 month and the rate in those treated medically are the same as that observed in SAMMPRIS. Less than half of the patients had been followed for 1 year, which may result in underestimation of ischemic events in patients who are medically managed. Our analysis supports the notion that if perioperative stroke and/or death in patients treated with PTAS can be reduced to <4%, PTAS has the potential to reduce the rate of recurrent ipsilateral stroke in patients with ipsilateral ischemic events and high-grade stenosis (70%–99%).

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

Kaplan-Meier curves for the cumulative probability of the primary end point after randomization in the PTAS and the medically treated groups in the SAMMPRIS trial and the probability in a hypothetical PTAS-treated cohort that provides the 35% relative risk reduction with PTAS treatment compared with medical treatment.

Alternatively, the medical community may consider a lower relative risk reduction with PTAS as clinically meaningful. The question is whether such periprocedural stroke and/or death rates can be achieved in PTAS procedures performed in selected settings and with careful selection of patients based on lesion characteristics and anatomic locations. Another issue that needs to be considered is the mandatory policy of stent placement once the patients were randomized into the PTAS group despite the anatomic factors such as proximal tortuosity and vessel dimensions. Primary angioplasty alone has been used for treatment of symptomatic intracranial stenosis and appears to be associated with lower periprocedural stroke and death rates6 and should be considered as an alternative to stent placement. The threshold of a 4% rate of periprocedural stroke and/or death with PTAS that is required to provide clinical benefit is probably the new standard for current clinical practice and future clinical trials.

Footnotes

  • Disclosures: Adnan Qureshi has received funding from the National Institutes of Health RO-1-NS44976–01A2 (medication provided by ESP Pharma, Edison, NJ) and the American Heart Association Established Investigator Award 0840053N, National Institutes of Health UO1-NS062091-O1A2, and the Minnesota Medical Foundation, Minneapolis, Minnesota.

References

  1. 1.↵
    SSYLVIA Study Investigators. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): study results. Stroke 2004;35:1388–92. Epub 2004 Apr 22
    Abstract/FREE Full Text
  2. 2.↵
    1. Chimowitz MI,
    2. Lynn MJ,
    3. Turan TN,
    4. et al
    . and SAMMPRIS Investigators. Design of the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis trial. J Stroke Cerebrovasc Dis 2011;20:357–68. Epub 2011 Sep 7
    CrossRefPubMed
  3. 3.↵
    1. Chimowitz MI,
    2. Lynn MJ,
    3. Derdeyn CP,
    4. et al
    . Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011;365:993–1003. Epub 2011 Sep 7
    CrossRefPubMed
  4. 4.↵
    1. Zaidat OO,
    2. Klucznik R,
    3. Alexander MJ,
    4. et al
    . The NIH registry on use of the Wingspan stent for symptomatic 70–99% intracranial arterial stenosis. Neurology 2008;70:1518–24. Epub 2008 Jan 30
    Abstract/FREE Full Text
  5. 5.↵
    1. Fiorella D,
    2. Levy EI,
    3. Turk AS,
    4. et al
    . US multicenter experience with the Wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results. Stroke 2007;38:881–87
    Abstract/FREE Full Text
  6. 6.↵
    1. Siddiq F,
    2. Vazquez G,
    3. Memon MZ,
    4. et al
    . Comparison of primary angioplasty with stent placement for treating symptomatic intracranial atherosclerotic diseases: a multicenter study. Stroke 2008;39:2505–10
    Abstract/FREE Full Text
  • © 2011 by American Journal of Neuroradiology
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 32 (11)
American Journal of Neuroradiology
Vol. 32, Issue 11
1 Dec 2011
  • Table of Contents
  • Index by author
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The New Standard for Performance of Intracranial Angioplasty and Stent Placement after Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis (SAMMPRIS) Trial
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The New Standard for Performance of Intracranial Angioplasty and Stent Placement after Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis (SAMMPRIS) Trial
S.A. Chaudhry, M. Watanabe, A.I. Qureshi
American Journal of Neuroradiology Dec 2011, 32 (11) E214; DOI: 10.3174/ajnr.A2919

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The New Standard for Performance of Intracranial Angioplasty and Stent Placement after Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis (SAMMPRIS) Trial
S.A. Chaudhry, M. Watanabe, A.I. Qureshi
American Journal of Neuroradiology Dec 2011, 32 (11) E214; DOI: 10.3174/ajnr.A2919
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Multicenter Prospective Trial of Stent Placement in Patients with Symptomatic High-Grade Intracranial Stenosis
  • Response to Critique of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial by Abou-Chebl and Steinmetz
  • Crossref
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

More in this TOC Section

  • Fair Performance of CT in Diagnosing Unilateral Vocal Fold Paralysis
  • Reply:
  • Regarding “Altered Blood Flow in the Ophthalmic and Internal Carotid Arteries in Patients with Age-Related Macular Degeneration Measured Using Noncontrast MR Angiography at 7T”
Show more LETTERS

Similar Articles

Advertisement

News and Updates

  • Lucien Levy Best Research Article Award
  • Thanks to our 2022 Distinguished Reviewers
  • Press Releases

Resources

  • Evidence-Based Medicine Level Guide
  • How to Participate in a Tweet Chat
  • AJNR Podcast Archive
  • Ideas for Publicizing Your Research
  • Librarian Resources
  • Terms and Conditions

Opportunities

  • Share Your Art in Perspectives
  • Get Peer Review Credit from Publons
  • Moderate a Tweet Chat

American Society of Neuroradiology

  • Neurographics
  • ASNR Annual Meeting
  • Fellowship Portal
  • Position Statements

© 2023 by the American Society of Neuroradiology | Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire